Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics in Drug Discovery

Julian Blagg's Biography

Julian Blagg, Deputy Director, Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research

Professor Julian Blagg is Deputy Director and Head of Chemistry of the Cancer Research UK Cancer Therapeutics Unit (CTU) at the Institute of Cancer Research (ICR), London, UK. An experienced and successful medicinal chemist, Professor Blagg joined the ICR in 2007 following 19 years medicinal chemistry and drug discovery experience in the pharmaceutical industry (Pfizer), both in the US and UK, where he was responsible for the successful progression of multiple preclinical development candidates into clinical trials across 4 therapeutic areas. He also developed expertise in compound features and physicochemical properties linked to toxicity, and in small molecule pharmacokinetics.
At the ICR, Professor Blagg works in close collaboration with clinical, genetics, biology, structural biology, computational and drug metabolism experts to discover and develop small molecule therapeutics for the treatment of cancer patients. He leads a personal research team with expertise in analytical, synthetic, medicinal and in silico medicinal chemistry. His team impacts from target identification and hit discovery through to the selection and progression of preclinical development candidates. He is Project Leader on multiple small molecule drug discovery programs across diverse protein classes.

Julian Blagg Image

Seeking Potent Selective and Cell Penetrant KDM4-Subfamily Inhibitors

Tuesday, 7 March 2017 at 11:15

Add to Calendar ▼2017-03-07 11:15:002017-03-07 12:15:00Europe/LondonSeeking Potent Selective and Cell Penetrant KDM4-Subfamily

This talk will describe our structure-based design approach towards the identification of potent JmjC histone demethylase inhibitors based upon the pyrido[3,4-d]pyrimidin-4(3H)-one scaffold which demonstrate potent and selective biochemical affinity for the KDM4 and KDM5 subfamily demethylases over the KDM2, KDM3 and KDM6 subfamilies and describe their cell-based activity profiles.

Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonEpigenetics in Drug